Myth Meets Molecules · Drug Toxicity & Preclinical Studies

1

Introduction — What is Drug Toxicity?

Definition, objectives, GLP principles, and animal selection criteria

1.1Definition & Objectives

▼

Drug toxicity: harmful, adverse, or undesirable effects produced by a drug when given in doses exceeding the therapeutic range.
Toxicity studies (preclinical): assess ALL relative toxic effects regarding dose, duration of exposure, and target organs.
Ethically and regulatory mandated — no new drug may enter human clinical trials without completing preclinical toxicity studies.
Also known as hyperpharmacology.

Objectives of Toxicity Studies

To identify any toxic substance PRIOR to clinical use in humans
Qualitative assessment (what organs are affected) and quantitative assessment (at what dose)
Characterise cumulative toxicity — especially in subchronic and chronic studies
Allow careful selection of safe doses for further studies, including carcinogenicity studies
Identify dose benchmarks: MLD, LD50, MTD, ED50
Calculate Therapeutic Index (TI) = LD50 / ED50 — measure of drug safety

1.2General Principles & GLP

▼

Must follow Good Laboratory Practice (GLP) — standardised rules for how laboratories conduct experiments
Studies must be performed by suitably trained and qualified staff
Instruments must be calibrated and standardised; SOPs must be followed at all times
All documents — protocol approval, raw data, draft reports, final reports, histology slides, paraffin tissue blocks — must be preserved for a minimum of 5 years after the drug reaches the market

1.3Animal Selection Criteria

▼

Parameter	Detail
Species required	At least TWO species — one must be a RODENT (rat or mouse)
Why two species?	Species-to-species variation in pharmacological responses — two species gives more reliable, generalisable data
Sex	Both males and females (to detect sex-specific toxicity)
Age of rodents	About 6 weeks; not more than 8 weeks at study start
Age of non-rodents (e.g. dogs)	4–6 months; not more than 9 months
Routes of administration	Two different routes must be used; one MUST be the route intended for human use

⚡ Exam Tip: "Why are two species used?" — Always answer: "to account for species-to-species variation in pharmacological responses." One species must always be a rodent.

2

Types of Toxicity Studies

Classified by duration — mirrors intended period of human use

Type	Duration / Nature
Acute	Single dose given in 24 hours; animals observed for 7–14 days
Subacute / Subchronic	Repeated doses given for 2 weeks to 6 months
Chronic	Repeated doses given for 6 months to 2 years
Special	Mutagenicity, Carcinogenicity, Reproductive toxicity, Local toxicity

Mnemonic

"A Sailor Can Sail" — Acute · Subacute · Chronic · Special

2.1Acute Toxicity Study (Single-Dose)

▼

The FIRST toxicity study done on any new drug. A single large dose (or several doses within 24 hours) is given and the animal is watched for 2 weeks.

Parameter	Detail
Animals	2 rodent species (mice AND rats); at least 5 animals/sex/group
Route	Same as intended for humans; if IV only → at least one more route also tested
Doses	At least 3 graded doses (low, medium, high)
Administration	Single bolus, several doses, or continuous infusion — all within 24 hours
Observation period	14 days after dosing
What is observed	Signs of intoxication · Body weight changes · Gross pathological changes (histopathology if gross changes seen)
Oral dose limit	2 g/kg OR 10× the intended human dose — whichever is HIGHER
Key calculations	MLD, MTD, LD50

⚡ Exam Tip: Oral acute toxicity test — dose limit is 2 g/kg OR 10× the intended human dose, whichever is HIGHER.

2.2LD50 — Definition, Methods & Karber's Worked Example

▼

LD50 (Lethal Dose 50): the dose that kills exactly 50% of the treated animals. First described by Trevan and Behrens.
Only ONE direct human LD50 was ever measured — all other values are from animal experiments.

Precautions

All animals must receive their dose on the SAME DAY, preferably at the SAME TIME
Laboratory conditions must be kept CONSTANT for each animal
Species, strain, age, weight, sex, and husbandry conditions all affect results

Methods of Calculating LD50

Method	Description
Karber's Method	Most common — simple, does NOT require plotting a curve. Formula-based.
Graphical (Miller-Tainter / Litchfield-Wilcoxon)	% response converted to PROBIT values, plotted as log dose vs probit. LD50 = antilog of x-value at probit 5.

Karber's Method — Formula & Worked Example

LD50 = Highest dose (100% mortality) − [Σ(DD × MM) / n]

Steps

1Record doses, n, number dead, and dose differences between groups

2Calculate Mean Mortality (MM) = (Dead prev group + Dead current group) / 2

3Calculate Dose Difference × Mean Mortality (DD × MM) for each group

4Sum all (DD × MM) values = Σ(DD × MM)

5Divide by n (animals per group)

6LD50 = Highest dose (100% mortality) − [Σ(DD × MM) / n]

Worked Example

Dose (mg/kg)	3	5	10	12	15	20
Deaths (n=10)	0	2	3	5	7	10

7Σ(DD × MM) = 84.5 → divide by n=10 → 8.45

8LD50 = 20 − 8.45 = 11.55 mg/kg

∴ LD50 = 11.55 mg/kg

Route-Related Rule of Thumb

Route	Relative LD50	Clinical Meaning
Oral (PO)	100% (Reference)	Most common route for toxicity testing
Intraperitoneal (IP)	~30% of oral LD50	IP LD50 ≈ 30% of the oral LD50
Intravenous (IV)	~10% of oral LD50	Most potent/dangerous route

⚡ Exam Tip: IV is the most dangerous route — requires the least drug to kill 50% of animals. IV LD50 ≈ 10% of oral LD50.

Probit Analysis

Converts a sigmoid dose-response curve into a straight line. Developed by Bliss (1939), refined by Finney (1952).
Requires at least 2 groups with PARTIAL responses (mortality > 0% but < 100%)
LD50 = antilog of log-dose value corresponding to probit 5 (= 50% mortality)

2.3Subacute / Subchronic Toxicity Study (Repeated-Dose)

▼

Purpose: Identify the TARGET ORGAN of toxicity and establish the Maximum Tolerated Dose (MTD) for subsequent studies.

Parameter	Detail
Animals	At least TWO species: 1 rodent + 1 non-rodent (e.g. dog); younger animals preferred
Duration options	14 days · 28 days · 90 days · 180 days
Rodent numbers	6–10/sex/group (14-day); 15–30/sex/group (90- and 180-day)
Non-rodent numbers	2–3/sex/group (14-day); 4–6/sex/group (90- and 180-day)
Route	Same as intended for human use
Doses	High = observable toxicity; Middle = some symptoms, no death; Lowest = no observable toxicity

Analytical Parameters Monitored

System	Parameters
Liver	Total bilirubin, direct/indirect bilirubin, bile acids, ammonia
Hepatocellular (leakage)	AST, ALT, SDH, LDH
Muscle	Creatine kinase (CK), AST, ALT, LDH
Pancreas	Amylase, lipase
Lipid / Cholestatic	Cholesterol, triglycerides; AP, GGT
Renal	Urea nitrogen, creatinine; urine specific gravity
Electrolytes	Calcium, potassium
Non-rodent only	ECG + fundus examination of eye

2.4Chronic Toxicity Study

▼

Done ONLY if the drug is intended for long-term use in humans (e.g. antihypertensives, antidiabetics, antiepileptics).

Intended Human Use Duration	Required Animal Testing Duration
Single dose or < 1 week	2 weeks to 1 month
1 week to 4 weeks	4 weeks to 3 months
1 to 6 months	3 to 6 months
> 6 months (long-term)	9 to 12 months (maximum)

⚡ Exam Tip: The length of animal toxicity testing ALWAYS mirrors the intended human use duration — a key regulatory principle.

3

Special Toxicity Studies

Mutagenicity · Carcinogenicity · Reproductive toxicity · Local toxicity · Safety pharmacology

Mnemonic

"My Cat Really Loves Sleeping" — Mutagenicity · Carcinogenicity · Reproductive · Local · Safety pharmacology

3.1Mutagenicity / Genotoxicity

▼

Parameter	Detail
Purpose	Determine whether the drug can damage DNA, cause mutations, or harm genetic material
In vitro tests	Reverse mutation test in bacteria (Ames test); Chromosomal aberration test with mammalian cells in culture
In vivo test	Micronucleus test with rodents
Most important test	Ames Test (Salmonella typhimurium reverse mutation test)
Principle of Ames Test	S. typhimurium normally REQUIRES histidine to grow. A mutagenic drug causes a back-mutation allowing growth WITHOUT histidine. Colonies growing without histidine = drug is mutagenic.
Significance	Mutagenic drug carries risk of cancer (carcinogenesis) or birth defects

⚡ Exam Tip: Ames test uses Salmonella typhimurium. Growth without histidine = mutagenic drug.

3.2Carcinogenicity Testing

▼

Purpose: determine whether long-term exposure can cause cancer (tumour formation)
When required: drug intended for long-term/lifelong use, OR if mutagenicity studies are positive
Design: Preliminary study → Full-scale carcinogenicity study in at least TWO species
Duration: often spans the lifetime of the animal (18–24 months in rodents)
Parameters observed: type of tumour, frequency of tumour development, onset, variety of organs involved

3.3Reproductive & Developmental Toxicity (3 Segments)

▼

Purpose: test the effect on the ENTIRE reproductive process — from fertilisation to development and behaviour of offspring.

Segment	What It Tests
Segment I	Fertility and early embryonic development
Segment II	Embryo-foetal development (teratogenicity) — structural malformations in the foetus when given during pregnancy
Segment III	Pre/postnatal development including lactation

3.4Local Toxicity Studies

▼

Done when the drug is intended for local use — e.g. eye drops, skin creams, vaginal gels.

Test Type	Animal	Details
Draize Test (Ocular)	Rabbits	Tests if ophthalmic drug irritates or damages the eye
Guinea Pig Maximisation Test (Skin)	Guinea pig	Freund's Complete Adjuvant Test — skin sensitisation
Other skin tests	Guinea pig	Buehler test · Patch test · Open epicutaneous test · Split adjuvant test · Optimisation test

⚡ Exam Tip: Draize test = eyes = rabbits. Guinea pig maximisation test = skin sensitisation. These animal-test associations are frequently examined.

4

Key Dose Terms

The most frequently tested definitions — know each one precisely

Term	Definition & Significance
LD50	Dose that kills exactly 50% of treated animals. Discovered by Trevan and Behrens. Karber's or Litchfield-Wilcoxon method.
MLD (Minimum Lethal Dose)	LOWEST dose that causes death in at least ONE animal
MTD (Maximum Tolerated Dose)	HIGHEST dose a subject can receive without causing death or severe irreversible toxicity. Sets highest dose for subacute/chronic studies.
ED50 (Effective Dose 50)	Dose that produces the desired therapeutic effect in 50% of animals
NOAEL	No Observable Adverse Effect Level — highest dose with NO adverse effects. Benchmark for safe first-in-human dose for non-cytotoxic drugs.
LOAEL	Lowest Observable Adverse Effect Level — LOWEST dose at which the FIRST adverse effect is detected (just above NOAEL)
TDL (Toxic Dose Low)	Lowest dose that produces any toxic effect. Used for cytotoxic drug dosing.
LD10	Dose lethal to 10% of animals. Used as safer starting point for cytotoxic drugs instead of NOAEL.

Safety Index & Therapeutic Index

Index	Formula & Meaning
Therapeutic Index (TI)	`TI = LD50 / ED50` — higher TI = safer drug (large gap between lethal and therapeutic dose)
Safety Index (SI)	Same formula in preclinical settings. MTD is later extrapolated to humans based on body weight, surface area, and physiological parameters.

⚡ Exam Tip: TI = LD50 / ED50. High TI = SAFE drug. Low TI = DANGEROUS drug (narrow margin between treatment and poisoning). Very common exam question.

5

Cytotoxic vs Non-Cytotoxic Drugs

Different approaches to calculating the first safe human dose

Drug Type	Approach	Rationale
Non-Cytotoxic (standard)	NOAEL approach → First human dose = NOAEL / safety factor (usually 10); mg/m² conversion	No toxicity is expected or acceptable
Cytotoxic (chemotherapy)	LD10 approach (NOT NOAEL)	Some toxicity is expected and accepted — must kill cancer cells. LD10 = safer, lower starting point.

⚡ Exam Tip: Key distinction — Non-cytotoxic = NOAEL. Cytotoxic = LD10. Examiners love this comparison.

Factors Complicating Dose Extrapolation

Non-monitorable toxicities (cannot be detected early with clinical tests)
Variable bioavailability between species
Irreversible toxicity (permanent damage even at low doses)
Unexpected toxicity not predicted by the animal model
Toxicities without prodromal (warning) indicators
Solution: Use a species with a SIMILAR toxicity profile to humans where possible

6

Organ-Specific (Target Organ) Toxicity

Key goal of subacute/chronic studies — which blood test corresponds to which organ

Organ / System	How Detected	Example Drugs
Hepatotoxicity (Liver)	↑ AST, ALT, LDH, SDH, bilirubin, bile acids, ammonia, AP, GGT; histopathology: necrosis, fatty change, cholestasis	Paracetamol overdose, Chloramphenicol
Nephrotoxicity (Kidney)	↑ Serum creatinine, BUN; altered urine specific gravity	Aminoglycosides (gentamicin), NSAIDs, contrast media
Cardiotoxicity (Heart)	ECG changes	R-bupivacaine; Digoxin (nausea + arrhythmias)
Neurotoxicity (NS)	Behavioural changes, neurological signs, specialised neuro tests	Vincristine (peripheral neuropathy)
Myotoxicity (Muscle)	↑ Creatine kinase (CK), AST, ALT, LDH	Statins (myopathy)
Pancreatic Toxicity	↑ Amylase, lipase; indicates pancreatitis	—
Reproductive Toxicity	Fertility studies, foetal malformations	—

⚡ Exam Tip: Liver = AST/ALT/Bilirubin · Kidney = Creatinine/BUN · Muscle = CK · Pancreas = Amylase/Lipase. Know which blood test corresponds to which organ.

7

Safety Pharmacology & GLP

ICH S7A core battery & Good Laboratory Practice requirements

7.1Safety Pharmacology — ICH S7A Core Battery

▼

Safety pharmacology vs toxicology: Toxicology studies harmful effects at HIGH supratherapeutic doses (mortality, organ damage). Safety pharmacology studies unwanted effects at THERAPEUTIC doses on vital organ function.
Required by ICH guidelines before Phase I clinical trials.

Organ System	Parameters Evaluated
Central Nervous System (CNS)	Behavioural effects, motor activity, coordination, sensory/motor reflexes, body temperature
Cardiovascular System	Blood pressure, heart rate, ECG (especially QT interval prolongation — risk of arrhythmia)
Respiratory System	Respiratory rate, tidal volume, oxygen saturation

7.2Good Laboratory Practice (GLP)

▼

Feature	Detail
Purpose of GLP	Ensure quality, integrity, and reproducibility of preclinical safety data. Allows regulatory authorities worldwide to trust submitted data.
Key requirements	Qualified trained staff · Calibrated equipment · SOPs · Proper documentation and data archiving · Quality Assurance (QA) oversight
Documentation period	All records preserved for minimum 5 years post-marketing
Regulatory bodies	India: CDSCO/DCGI · USA: FDA · UK: MHRA · WHO guidelines followed internationally

7.3Regulatory Pathway — IND Application

▼

Once all preclinical studies are complete, the company applies for the IND (Investigational New Drug) Application — permission to test the drug in humans.

Step	Detail
IND Application	Submitted to national drug regulatory authority BEFORE starting clinical trials
India	Submitted to DCGI (Drug Controller General of India) under CDSCO
USA	Submitted to FDA
UK	Submitted to CSM/MHRA
Contents	Preclinical data (pharmacology, toxicology, PK) + Manufacturing info + Clinical trial protocol + Investigator information
After approval	Phase I clinical trials (first in human) can begin

10

Master Revision Table & High-Yield Facts

All toxicity studies at a glance + 12 top exam facts + mnemonics

Type	Animals	Duration	Key Goal	Key Parameters
Acute	2 rodent species; ≥5/sex/group	Single dose; observe 14 days	LD50, MLD, MTD	Signs of intoxication, body weight, gross pathology
Subacute / Subchronic	1 rodent + 1 non-rodent; 6–30/sex	14 days to 6 months	Target organ; MTD	Blood biochemistry, haematology, histopathology, ECG
Chronic	1 rodent + 1 non-rodent	6 months to 2 years	Long-term safety	Same as subacute; body weight, LFT, RFT, histopathology
Mutagenicity	Bacteria + mammalian cells + rodents	Short (in vitro + in vivo)	DNA damage	Ames test, chromosomal aberration, micronucleus
Carcinogenicity	2 species	Lifetime (18–24 months)	Tumour induction	Tumour type, frequency, onset, organ
Reproductive	Rodents + non-rodents	3 segments	Fertility, foetal safety	Malformations, fertility indices, offspring behaviour
Local Toxicity	Guinea pig / Rabbit	Days to weeks	Site-specific safety	Draize (eye), Maximisation test (skin)

Top 12 High-Yield Facts

1. LD50 = dose that kills 50% of treated animals. Discovered by Trevan and Behrens.
2. Two animal species always required: 1 rodent + 1 non-rodent. One MUST be a rodent.
3. Karber's Method: LD50 = Highest dose (100% mortality) − [Σ(DD × MM) / n]
4. Route rule: IP LD50 ≈ 30% of oral; IV LD50 ≈ 10% of oral
5. Acute toxicity: single dose, 24 h, observe 14 days. Oral limit = 2 g/kg or 10× human dose (higher).
6. Subacute: target organ identification. MTD. Duration: 14 days to 6 months.
7. Chronic: only if drug intended for long-term use. Duration: 6 months to 2 years.
8. Ames Test: Salmonella typhimurium. Growth without histidine = mutagenic drug.
9. NOAEL used for non-cytotoxic drugs. LD10 used for cytotoxic drugs.
10. Therapeutic Index = LD50 / ED50. Higher TI = Safer drug.
11. Draize test = ocular (eye) local toxicity. Animal: Rabbit.
12. Guinea pig maximisation test = skin sensitisation test.

Mnemonics

"A Sailor Can Sail" → Acute · Subacute · Chronic · Special
"My Cat Really Loves Sleeping" → Mutagenicity · Carcinogenicity · Reproductive · Local · Safety pharmacology
Organ blood tests: Liver = AST/ALT/Bili · Kidney = Creatinine/BUN · Muscle = CK · Pancreas = Amylase/Lipase

Drug Toxicity &Preclinical Studies